Background <p>Cervical cancer is a major challenge facing women’s health worldwide. In China, its incidence and mortality rate rank first among female reproductive tract malignancies. SNHG15 has been found and proven to have important functions in many cancers. Related studies have shown that miR-200a-3p plays an important role in tumor development. However, there is little research on how the two are involved in the progression of cervical cancer cells and their potential regulatory systems.</p> Methods <p>qRT-PCR was used to detect the expression of LncRNA SNHG15 in human cervical immortalized squamous cells (Ect1/E6E7) and human cervical cancer cell lines (SiHa, HeLa, Caski, C-33&#xa0;A). Cervical cancer HeLa and SiHa cells were used as the research objects and were divided into NC, GV493-negative group, SNHG15-shRNA group, empty vector group, and SNHG15-OERNA group. The expression levels of LncRNA SNHG15 and miR-200a-3p in cells were detected by qRT-PCR. CCK8 was used to detect cell proliferation, cell migration and invasion ability, and dual luciferase activity was used to analyze the targeted binding of LncRNA SNHG15 and miR-200a-3p.</p> Results <p>Compared with human cervical immortalized squamous cells (Ect1/E6E7), the expression level of LncRNA SNHG15 in human cervical cancer cell lines SiHa, HeLa and C-33&#xa0;A was increased(<i>P</i>&lt;0.05). Cervical cancer cells HeLa and SiHa with more significant differences were selected for subsequent studies. Overexpression of LncRNA SNHG15 or low expression of miR-200a-3p promoted cell proliferation, migration and invasion (<i>P</i> <i>&lt; 0.05</i>).</p> Conclusion <p>High expression of SNHG15 progression cervical cancer cell proliferation, migration, and invasion by targeting the miR-200a-3p gene.</p> Trial Registration <p>Trial registration: DRKS, ISRCTNDRKS00035987. Registration on 17 February 2025—Retrospectively registered, <a href="https://drks.de/register/de/trial/DRKS00035987">https://drks.de/register/de/trial/DRKS00035987</a></p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

LncRNA SNHG15 targets miR-200a-3p affects the proliferation, apoptosis, migration, and invasion of cervical cancer cells

  • Songtao Han,
  • Yajuan Qin,
  • YuJiao He,
  • Ming Li,
  • Jing Ma,
  • Ning Luo,
  • Yishan Huo,
  • Xinling Meng,
  • Yunmei Liu

摘要

Background

Cervical cancer is a major challenge facing women’s health worldwide. In China, its incidence and mortality rate rank first among female reproductive tract malignancies. SNHG15 has been found and proven to have important functions in many cancers. Related studies have shown that miR-200a-3p plays an important role in tumor development. However, there is little research on how the two are involved in the progression of cervical cancer cells and their potential regulatory systems.

Methods

qRT-PCR was used to detect the expression of LncRNA SNHG15 in human cervical immortalized squamous cells (Ect1/E6E7) and human cervical cancer cell lines (SiHa, HeLa, Caski, C-33 A). Cervical cancer HeLa and SiHa cells were used as the research objects and were divided into NC, GV493-negative group, SNHG15-shRNA group, empty vector group, and SNHG15-OERNA group. The expression levels of LncRNA SNHG15 and miR-200a-3p in cells were detected by qRT-PCR. CCK8 was used to detect cell proliferation, cell migration and invasion ability, and dual luciferase activity was used to analyze the targeted binding of LncRNA SNHG15 and miR-200a-3p.

Results

Compared with human cervical immortalized squamous cells (Ect1/E6E7), the expression level of LncRNA SNHG15 in human cervical cancer cell lines SiHa, HeLa and C-33 A was increased(P<0.05). Cervical cancer cells HeLa and SiHa with more significant differences were selected for subsequent studies. Overexpression of LncRNA SNHG15 or low expression of miR-200a-3p promoted cell proliferation, migration and invasion (P< 0.05).

Conclusion

High expression of SNHG15 progression cervical cancer cell proliferation, migration, and invasion by targeting the miR-200a-3p gene.

Trial Registration

Trial registration: DRKS, ISRCTNDRKS00035987. Registration on 17 February 2025—Retrospectively registered, https://drks.de/register/de/trial/DRKS00035987